

Haematologica
HAEMATOL/2015/128728
Version 4

Reduced relapse rate in upfront tandem autologous/reduced intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression free and not of overall survival

Disclosures: Disclosures of Conflict of interest: H.M.L served as a consultant and received research support from Genmab and Janssen. P.S has received research support from Onyx, Janssen and Celgene. M.J.K. has received research support from Celgene and honoraria from Celgene and Janssen. S.Z has received from and served on the advisory boards of Janssen, Celgene and Millenium. M.v.O: consultant Roche, GSK and Genmab. G.B has received research support from Celgene. M.C.M served as a consultant for Janssen, Amgen and Novartis. N.S. Advisory board Novartis. R.R. Advisory board Novartis, Roche. All other authors have nothing to disclose.

Contributions: Authorship Contributions: H.M.L., B.v.d.H. and P.S. contributed to study conception and design; H.M.L., B.v.d.H., J.J.C., M.-J.K., M.v.O., R.R., M.C.M., S.Z., G.B., N.S., S.W., O.d.W., R.A., and P.S. collected and assembled the data; H.M.L., B.v.d.H., R.A., and P.S. conducted data analysis and interpretation; and all authors were involved in manuscript writing and approved the final version of the manuscript.